Document:

EX-10.7

 Exhibit 10.7 

February 28, 2019 
 Quoc
Le-Nguyen 
 Dear Quoc: 

Offer and Position 
 We are very pleased to extend an offer
of employment to you for the position of Chief Technical Operations Officer (“CTO”) of 89bio Ltd. (the “Company”). This offer of employment is conditioned on your satisfactory completion of certain requirements, as
more fully explained in this letter. Your employment is subject to the terms and conditions set forth in this letter. Your employment will be administered under a US subsidiary of the Company. 

Duties 
 In your capacity as a CTO, you will perform
duties and responsibilities that are commensurate with your position and such other duties as may be assigned to you by the CEO from time to time, provided that such duties are consistent with your position. You will report directly to Chief
Executive Officer (CEO) of the company. You agree to devote your full business time, attention and best efforts to the performance of your duties and to the furtherance of the Company’s interests. 

Location 
 Your principal place of employment shall in the
San Francisco Bay area, subject to business travel as needed to properly fulfil your employment duties and responsibilities. 
 Start Date 

Subject to satisfaction of all of the conditions described in this letter, your anticipated start date is March 18, 2019. 

Base Salary 
 In consideration of your services, you will
be paid an initial base salary of $340,000 per year, subject to review for increase only by the Chief Executive Officer and Board from time to time, payable in accordance with the standard payroll practices of the Company or its US subsidiary and
subject to all withholdings and deductions as required by law. 

 Annual Bonus 

Each year, you will have an opportunity to earn a target bonus of 30% of your base salary (the “Target Bonus”). Your actual bonus amount will
be determined based on a combination of Company results and individual performance against the applicable performance goals established by the CEO. 
 Any
annual bonus with respect to a particular calendar year will be paid within 4 months following the end of the year for which the annual bonus relates. For any partial year of employment you will receive a
pro-rated annual bonus based on the number of days you are employed during the year. 
 You must remain continuously
employed through the end of the applicable calendar year to be eligible to receive an annual bonus payment for a particular calendar year. 
 Expenses

 The Company or its US subsidiary will reimburse you only for out of pocket business related expenses reasonably incurred in the performance of your
duties, as approved by the Board in the annual budgeting process and in accordance with any expense claiming policies and guidelines promulgated by the Company or its US subsidiary from time to time. 

Equity Grants 
 As soon as practicable following the Start
Date, the Company will recommend that the Board grant you an option to purchase an aggregate of 404,159 Ordinary Shares of the Company (representing 1.00% of the issued and outstanding shares of the Company as of the close of the Series A 2nd tranche), at a per share exercise price equal to the fair market value of such shares on the date of grant. The Company will recommend to the Board that such 1.00% stake be trued up if and when the
Company closes the third tranche of its Series A financing. The options will be governed by the Company’s 2018 Equity Incentive Plan (as supplemented by the Company’s 2018 United States Sub-Plan) and
a stock option agreement to be entered into between the Company and you. The stock option agreement will provide, among other things, that, (i) subject to your continued employment with the Company or its subsidiary on each applicable vesting
date, your options shall vest over a four-year period, 25% upon the one-year anniversary of the Start Date (or the third tranche date in respect of any true up grant), and the remaining 75% in equal quarterly
instalments over a period of three years thereafter, and (ii) in the event that you are terminated without Cause (as defined below) or resign for Good Reason (as defined below) within the Change in Control Protection Period (as defined below),
then, subject to the Release Condition described below, any of your options then subject to vesting shall become fully vested as of the date of such termination. 

Benefits and Perquisites 
 You will be eligible to
participate in the employee benefit plans and programs generally available to the Company’s senior executives in the United States. You will be entitled to paid vacation in accordance with the Company’s or its US subsidiary’s policies
in effect from time to time. The Company and its subsidiaries reserve the right to amend, modify or terminate any of its benefit plans or programs at any time and for any reason. 

  
 2 

 Withholding 

All forms of compensation paid to you as an employee of the Company or its subsidiary shall be less all applicable withholdings. 

At-will Employment 

Your employment with the Company or its subsidiary will be for no specific period of time. Rather, your employment will be
at-will, meaning that any party may terminate the employment relationship at any time, with or without cause, and with or without notice and for any reason or no particular reason. Although your
compensation and benefits may change from time to time, the at-will nature of your employment may only be changed by an express written agreement signed by both you and the Chief Executive Officer. 

Severance outside of Change in Control Protection Period 

If your employment with the Company or its subsidiary is involuntarily terminated by the Company without Cause (as defined below) and not due to a breach by
you of the terms and conditions of this letter (including, but not limited to, a breach of any of the representations contained herein, the enclosed Employee Proprietary Information and Invention Assignment Agreement (the “PIIA”) or
the Employee Arbitration Agreement) at any time outside of the Change in Control Protection Period (as defined below), subject to your execution of a release of claims in a form provided by the Company, you will be eligible to receive severance in
an amount equal to: (i) three (3) months of base salary at the rate then in effect, (ii) a pro-rata amount of the Target Bonus based on the number of months you were employed with the Company for the
year in which your employment is terminated and (iii) subject to your timely election under COBRA, payment or reimbursement of a portion of your COBRA premiums for three (3) months following your termination or, if earlier, until such time
as you become eligible for similar coverage through another employer, which benefits shall be paid for by the Company to the same extent that the Company paid for health insurance for your prior to termination, (such amounts described in clauses
(i) through (iii) herein, collectively, the “Severance Benefits”). You will thereafter be responsible for the payment of COBRA premiums (including, without limitation, all administrative expenses) for any remaining COBRA
period. Notwithstanding the foregoing, in the event that the Company determines, in its sole discretion, that the Company may be subject to a tax or penalty pursuant to Code Section 4980D as a result of providing some or all of the payments
described in this paragraph, the Company may reduce or eliminate its obligations under this paragraph to the extent it deems necessary, with no offset or other consideration required. The Severance Benefits will be payable or provided in regular
instalments in accordance with the Company’s or its subsidiary’s normal payroll practices over a period of three (3) months commencing on the first payroll date following the date on which the Release Condition is satisfied or in a
cash lump sum, solely at the discretion of the Board. For purposes herein, the “Release Condition” means your execution, delivery, and non-revocation of the release within 45 days following
your termination of employment and “Cause” means a reasonable, good faith finding by the Chief Executive Officer or the Board that you: (i) committed, been convicted of, or entered a plea of guilty or nolo contendere or no
contest with respect to, (x) any felony or (y) any misdemeanour involving dishonesty or moral turpitude; (ii) engaged in gross negligence, wilful misconduct, or any bad-faith act that is, or
could reasonably 

  
 3 

 
be expected to be, materially injurious to the business or reputation of the Company; (iii) committed an act of fraud, embezzlement, theft, or misappropriation against the Company or
otherwise in the course of your employment with, or the performance of duties for, the Company; (iv) substantially failed to perform your duties in respect of your employment diligently and in a manner consistent with prudent business practice;
(v) failed to execute and carry out any reasonable lawful directive of the Chief Executive Officer or the Board that is related to the business of the Company; or (vi) engaged in any act or omission that is materially injurious the
business, financial condition, or operations of the Company. 
 Severance During the Change in Control Protection Period 

In the event you are terminated without Cause or resign for Good Reason (as defined below) within ninety (90) days prior to, or twelve (12) months
following the consummation of a Change in Control (the “Change in Control Protection Period”), then, subject to the Release Condition described above, the amount of the Severance Benefits described above will be six (6) instead
of three (3) and will be paid or provided over six (6) months (instead of 3-months, unless the Board determines to pay or provide such Severance Benefits in a cash lump sum in sole discretion) plus
any then outstanding equity then held by you that is unvested, will vest in full. For purposes herein, “Change in Control” means an event (i) which constitutes a Deemed Liquidation Event as defined in the Company’s
Articles of Association, as may be amended from time to time, and (ii) in which the Company’s Series A investors receive a multiple of invested capital of at least two (2) times their original investment, and “Good
Reason” means your resignation based on any of the following events without your written consent, (a) a material diminution in your authority, duties or responsibilities; (b) a material diminution in reporting relationship from
that determined by an acquirer at the time of such Change of Control; (c) a material diminution in your annual base salary except if the base salaries of a significant number of other executives and members of senior management of the Company
also are proportionately reduced, whether or not such reduction is voluntary on your part or on the part of such other executives and senior management; (d) the Company’s relocation of your primary work location outside a 40-mile radius of San Francisco that increases your one-way driving distance by more than 40 miles; (e) any other action or inaction that constitutes a material breach of
the terms of an applicable employment agreement. To constitute a resignation for Good Reason: (i) you must provide written notice to the Company within thirty (30) days of the initial existence of the event constituting Good Reason,
(ii) you may not terminate your employment unless the Company fails to remedy the event constituting Good Reason within fifteen (15) days after such notice has been deemed given pursuant to this offer letter, and (iii) you must
terminate employment with the company no later than fifteen (15) days after the end of the 15-day cure period in which the Company fails to remedy the event constituting Good Reason. 

Section 409A 
 This offer letter is intended to
comply with Section 409A of the Internal Revenue Code (“Section 409A”) or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Notwithstanding any other
provision of this offer letter, payments provided under this offer letter may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this offer letter that may be excluded from
Section 409A either as separation pay due to an involuntary 

  
 4 

 
separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes of Section 409A, each instalment payment provided
under this offer letter shall be treated as a separate payment. Any payments to be made under this offer letter upon a termination of employment shall only be made upon a “separation from service” under Section 409A. Notwithstanding
the foregoing, the Company makes no representations that the payments and benefits provided under this offer letter comply with Section 409A and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or
other expenses that may be incurred by you on account of noncompliance with Section 409A. 
 Notwithstanding any other provision of this offer letter,
if any payment or benefit provided to you in connection with termination of employment is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A and you are determined to be a “specified
employee” as defined in Section 409A(a)(2)(b)(i), then such payment or benefit shall not be paid until the first payroll date to occur following the six-month anniversary of your termination date
(the “Specified Employee Payment Date”) or, if earlier, on the date of your death. The aggregate of any payments that would otherwise have been paid before the Specified Employee Payment Date shall be paid to you in a lump sum on
the Specified Employee Payment Date and thereafter, any remaining payments shall be paid without delay in accordance with their original schedule. Whenever in this offer letter a payment or benefit is conditioned on your execution of a release of
claims, such release must be executed, and all revocation periods shall have expired, within 45-days after the date of your termination of employment, failing which such payment or benefit shall be forfeited.
If such payment or benefit constitutes non-exempt deferred compensation for purposes of Section 409A, and if such 45-day period begins in one calendar year and ends
in the next calendar year, the payment or benefit shall not be made or commence before the second such calendar year, even if the release becomes irrevocable in the first such calendar year. 

Governing Law 
 This offer letter shall be governed by the
laws of California, without regard to conflict of law principles. 
 Contingent Offer 

This offer is contingent upon: 
 (a) Verification
of your right to work in the United States, as demonstrated by your completion of an I-9 form upon hire and your submission of acceptable documentation (as noted on the
I-9 form) verifying your identity and work authorization within three days of your Start Date. For your convenience, a copy of the I-9 Form’s List of Acceptable
Documents is enclosed for your review. 
 (b) Your execution of the Company’s enclosed (1) Employee Proprietary Information and
Invention Assignment Agreement, and (2) Employee Arbitration Agreement. 

  
 5 

 Representations and Warranties 

By accepting this offer, you represent that you are able to accept this job and carry out the work that it would involve without breaching any legal
restrictions on your activities, such as non-competition, non-solicitation or other work-related restrictions imposed by a current or former employer. You also represent
that you will inform the Company about any such restrictions and provide the Company with as much information about them as possible, including any agreements between you and your current or former employer describing such restrictions on your
activities. You further confirm that you will not remove or take any documents or proprietary data or materials of any kind, electronic or otherwise, with you from your current or former employer to the Company without written authorization from
your current or former employer, nor will you use or disclose any such confidential information during the course and scope of your employment with the Company. If you have any questions about the ownership of particular documents or other
information, you should discuss such questions with your former employer before removing or copying the documents or information. 
 By accepting this
offer, you acknowledge and agree that, so long as you are employed by the Company or its subsidiary, except upon the prior written consent of the Chief Executive Officer, you will not (i) accept any other employment, or (ii) engage,
directly or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that is or may be in conflict with, or that might place you in a conflicting position to that of, the Company. 

We are excited at the prospect of you joining our team. If you have any questions about the above details, please call me. If you wish to accept this
position, please sign below and return this letter to me. This offer is open for you to accept through March 3, 2019, at which time it will be deemed to be withdrawn. 

I look forward to hearing from you. 
 Yours sincerely, 

Rohan Palekar 
 On behalf of 89bio Ltd. 

Signed /s/ Rohan Palekar 
 Date February 28, 2019

  
 6 

 Acceptance of Offer 

I have read, understood and accept all the terms of the offer of employment as set forth in the foregoing letter. I have not relied on any agreements or
representations, express or implied, that are not set forth expressly in the foregoing letter, and this letter supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect
to the subject matter of this letter. 
 Quoc Le-Nguyen 

Signed /s/ Quoc
Le-Nguyen                     

Date March 1, 2019 

  
 7EX-10.8

 Exhibit 10.8 
  

 
 July 21, 2019 
 Ryan
Martins 
 Dear Ryan, 
 Offer and Position 

We are very pleased to extend an offer of employment to you for the position of Chief Financial Officer (“CFO”) of 89bio Ltd.
(the “Company”). This offer of employment is conditioned on your satisfactory completion of certain requirements, as more fully explained in this letter. Your employment is subject to the terms and conditions set forth in
this letter. Your employment will be administered under a US subsidiary of the Company. 
 Duties 

In your capacity as a CFO, you will perform duties and responsibilities that are commensurate with your position and such other duties as may be assigned to
you from time to time. You will report directly to the Chief Executive Officer, (the “CEO”). You agree to devote your full business time, attention and best efforts to the performance of your duties and to the furtherance of
the Company’s interests. 
 Location 
 Your
principal place of employment shall in the San Francisco Bay area, subject to business travel as needed to properly fulfil your employment duties and responsibilities. 

Start Date 
 Subject to satisfaction of all of the
conditions described in this letter, your anticipated start date is July 21, 2019 (“Start Date”). 
 Base Salary 

In consideration of your services, you will be paid an initial base salary of $330,000 per year, subject to review by the Board from time to time, payable in
accordance with the standard payroll practices of the Company or its US subsidiary and subject to all withholdings and deduct ions as required by law. 

Annual Bonus 
 Each year, you will have an opportunity to
earn a bonus of up to 30% of your base salary (the “Target Bonus”). Your actual bonus amount will be determined based on a combination of Company results and individual performance against the applicable performance goals
established by the Board. Any annual bonus with respect to a particular calendar year will be paid within 2 

  
 89bio LTD., 6
Hamada Street, 4th Floor, Herzliya, Israel 
 535 Mission Street, San Francisco, CA 94105

 

 
  

 
1/2 months following the end of the year for which the annual bonus relates. For any partial year of employment, you will receive a pro-rated annual bonus
based on the number of days you are employed during the year. 
 You must remain continuously employed through the end of the applicable calendar year to be
eligible to receive an annual bonus payment for a particular calendar year. 
 Expenses 

The Company or its US subsidiary will reimburse you only for out of pocket business related expenses reasonably incurred in the performance of your duties, as
approved by the Board in the annual budgeting process and in accordance with any expense claiming policies and guidelines promulgated by the Company or its US subsidiary from time to time. 

Equity Grants 
 As soon as practicable following the Start
Date, the Company will recommend that the Board grant you an option to purchase an aggregate of 590,000 of shares Ordinary Shares of the Company (representing ~1.04% of the current fully diluted outstanding shares of the Company), at a per share
exercise price equal to the fair market value of such shares on the date of grant based on the last 409A Valuation. The Company will recommend to the Board that your percentage ownership in the company be trued up through the end of its Series A
financing. The options will be governed by the Company’s 2018 Equity Incentive Plan (as supplemented by the Company’s 2018 United States Sub-Plan) and a stock option agreement to be entered into
between the Company and you. The stock option agreement will provide, among other things, that, (i) subject to your continued employment with the Company or its subsidiary on each applicable vesting date, your options shall vest over a
four-year period, 25% upon the one-year anniversary of the Start Date (or the fourth tranche date in respect of any true up grant), and the remaining 75% in equal quarterly installments over a period of three
years thereafter, and (ii) in the event that you are terminated without Cause (as defined below) or resign for Good Reason (as defined below) within the Change in Control Protection Period (as defined below), then, subject to the Release
Condition described below, any of your options then subject to vesting shall become fully vested as of the date of such termination. 
 Benefits and
Perquisites 
 You will be eligible to participate in the employee benefit plans and programs generally available to the Company’s senior executives
in the United States, as those policies are developed and amended by the Company. You will be entitled to paid vacation in accordance with the Company’s or its US subsidiary’s policies in effect from time to time. The Company and its
subsidiaries reserve the right to amend, modify or terminate any of its benefit plans or programs at any time and for any reason. 
 Withholding 

All forms of compensation paid to you as an employee of the Company or its subsidiary shall be less all applicable withholdings. 

  
 89bio LTD., 6
Hamada Street, 4th Floor, Herzliya, Israel 
 535 Mission Street, San Francisco, CA 94105

 

 
  

 At-will Employment 

Your employment with the Company or its subsidiary will be for no specific period of time. Rather, your employment will be
at-will, meaning that any party may terminate the employment relationship at any time, with or without cause, and with or without notice and for any reason or no particular reason. Although your
compensation and benefits may change from time to time, the at-will nature of your employment may only be changed by an express written agreement signed by an authorized officer of the Company after approval
by the Board. 
 Severance During the Change in Control Protection Period 

In the event you are terminated without Cause or resign for Good Reason (as defined below) within ninety (90) days prior to, or twelve (12) months
following the consummation of a Change in Control (the “Change in Control Protection Period”), then, subject to the Release Condition described above, the amount of the Severance Benefits described above will be six
(6) months paid over six (6) months, unless the Board determines to pay or provide such Severance Benefits in a cash lump sum in sole discretion) plus any then outstanding equity then held by you that is unvested, will vest in full. For
purposes herein, “Change in Control” means an event (i) which constitutes a Deemed Liquidation Event as defined in the Company’s Articles of Association, as may be amended from time to time, and (ii) in which
the Company’s Series A investors receive a multiple of invested capital of at least two (2) times their original investment, and “Good Reason” means your resignation based on any of the following events
without your written consent, (a) a material diminution in your authority, duties or responsibilities; (b) a material diminution in reporting relationship from that determined by an acquirer at the time of such Change of Control;
(c) a material diminution in your annual base salary except if the base salaries of a significant number of other executives and members of senior management of the Company also are proportionately reduced, whether or not such reduction is
voluntary on your part or on the part of such other executives and senior management; (d) the Company’s relocation of your primary work location outside a 40-mile radius of San Francisco that
increases your one-way driving distance by more than 40 miles; (e) any other action or inaction that constitutes a material breach of the terms of an applicable employment agreement. To constitute a
resignation for Good Reason: (i) you must provide written notice to the Company within thirty (30) days of the initial existence of the event constituting Good Reason, (ii) you may not terminate your employment unless the Company
fails to remedy the event constituting Good Reason within fifteen (15) days after such notice has been deemed given pursuant to this offer letter, and (iii) you must terminate employment with the company no later than fifteen
(15) days after the end of the 15-day cure period in which the Company fails to remedy the event constituting Good Reason. 

Section 409A 
 This offer letter is intended to
comply with Section 409A of the Internal Revenue Code (“Section 409A”) or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Notwithstanding any other
provision of this offer letter, payments provided under this offer letter may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this offer letter that may be excluded from
Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes

  
 89bio LTD., 6
Hamada Street, 4th Floor, Herzliya, Israel 
 535 Mission Street, San Francisco, CA 94105

 

 
  

 
of Section 409A, each instalment payment provided under this offer letter shall be treated as a separate payment. Any payments to be made under this offer letter upon a termination of
employment shall only be made upon a “separation from service” under Section 409A. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this offer letter comply with
Section 409A and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by you on account of noncompliance with Section 409A. 

Notwithstanding any other provision of this offer letter, if any payment or benefit provided to you in connection with termination of employment is determined
to constitute “nonqualified deferred compensation” within the meaning of Section 409A and you are determined to be a “specified employee” as defined in Section 409A(a)(2)(b)(i), then such payment or benefit shall not be
paid until the first payroll date to occur following the six-month anniversary of your termination date (the “Specified Employee Payment Date”) or, if earlier, on the date of your
death. The aggregate of any payments that would otherwise have been paid before the Specified Employee Payment Date shall be paid to you in a lump sum on the Specified Employee Payment Date and thereafter, any remaining payments shall be paid
without delay in accordance with their original schedule. Whenever in this offer letter a payment or benefit is conditioned on your execution of a release of claims, such release must be executed, and all revocation periods shall have expired,
within 45-days after the date of your termination of employment, failing which such payment or benefit shall be forfeited. If such payment or benefit constitutes
non-exempt deferred compensation for purposes of Section 409A, and if such 45-day period begins in one calendar year and ends in the next calendar year, the payment
or benefit shall not be made or commence before the second such calendar year, even if the release becomes irrevocable in the first such calendar year. 

Governing Law 
 This offer letter shall be governed by the
laws of California, without regard to conflict of law principles. 
 Contingent Offer 

This offer is contingent upon: 
  

	 	(a)	 Verification of your right to work in the United States, as demonstrated by your completion of an I-9 form upon hire and your submission of acceptable documentation (as noted on the I-9 form) verifying your identity and work authorization within three days of your Start
Date. For your convenience, a copy of the I-9 Form’s List of Acceptable Documents is enclosed for your review. 

  

	 	(b)	 Your execution of the Company’s enclosed (1) Employee Proprietary Information and Invention
Assignment Agreement, and (2) Employee Arbitration Agreement. 

 Representations and Warranties 

By accepting this offer, you represent that you are able to accept this job and carry out the work that it would involve without breaching any legal
restrictions on your activities, such as non -competition, non-solicitation or other work-related restrictions imposed by a current or former 

  
 89bio LTD., 6
Hamada Street, 4th Floor, Herzliya, Israel 
 535 Mission Street, San Francisco, CA 94105

 

 
  

 
employer. You also represent that you will inform the Company about any such restrictions and provide the Company with as much information about them as possible, including any agreements between
you and your current or former employer describing such restrictions on your activities. You further confirm that you will not remove or take any documents or proprietary data or materials of any kind, electronic or otherwise, with you from your
current or former employer to the Company without written authorization from your current or former employer, nor will you use or disclose any such confidential information during the course and scope of your employment with the Company. If you have
any questions about the ownership of particular documents or other in formation, you should discuss such questions with your former employer before removing or copying the documents or information. 

By accepting this offer, you acknowledge and agree that, so long as you are employed by the Company or its subsidiary, except upon the prior written consent
of the Board, you will not (i) accept any other employment, or (ii) engage, directly or indirectly , in any other business activity (whether or not pursued for pecuniary advantage) that is or may be in conflict with, or that might place
you in a conflicting position to that of, the Company. 
 We are excited at the prospect of you joining our team. If you have any questions about the above
details, please call me immediately. If you wish to accept this position, please sign below and return this letter to me. This offer is open for you to accept through July 22, 2019, at which time it will be deemed to be withdrawn. 

I look forward to hearing from you. 
  

	
	Yours sincerely,
	
	/s/ Rohan Palekar                    
	
	Rohan Palekar
	Chief Executive Officer
	On behalf of 89bio Ltd.

  
 89bio LTD., 6
Hamada Street, 4th Floor, Herzliya, Israel 
 535 Mission Street, San Francisco, CA 94105

 

 
  

 Acceptance of Offer 

I have read, understood and accept all the terms of the offer of employment as set forth in the foregoing letter. I have not relied on any agreements or
representations, express or implied, that are not set forth expressly in the foregoing letter, and this letter supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect
to the subject matter of this letter. 
 Ryan Martins 

Signed: /s/ Ryan
Martins                                 

Date: July 21,
2019                                         

  
 89bio LTD., 6
Hamada Street, 4th Floor, Herzliya, Israel 
 535 Mission Street, San Francisco, CA 94105

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]